Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2021 - 2024)
Protagonist Therapeutics (PTGX) reported Amortization of Deferred Charges of $418000.0 for Q4 2024, down 28.42% on a YoY basis from $584000.0 in Q1 2024, and little changed sequentially from $416000.0 in Q3 2024.
Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2021 - 2024) Analysis & Trends
Protagonist Therapeutics (PTGX) has 4 years of Amortization of Deferred Charges data on file, last reported at $418000.0 in Q4 2024.
- For the quarter ending Q4 2024, Amortization of Deferred Charges fell 28.42% year-over-year to $418000.0; the trailing twelve-month figure through Dec 2024 stood at $2.1 million (down 11.39% YoY), and the FY2024 full-year result was $2.1 million, down 11.39% from the prior year.
- Amortization of Deferred Charges was little changed at $418000.0 in Q4 2024, from $416000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $651000.0 in Q2 2024 to a low of $416000.0 in Q3 2024.
- A 4-year average of $543812.5 and a median of $584000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges soared 31.83% in 2022 and declined 28.64% in 2024, its largest moves.
- Tracing PTGX's Amortization of Deferred Charges over 4 years: stood at $584000.0 in 2021, then changed by 0.0% to $584000.0 in 2022, then changed by 0.0% to $584000.0 in 2023, then retreated by 28.42% to $418000.0 in 2024.
- Business Quant data shows PTGX's Amortization of Deferred Charges at $418000.0 in Q4 2024, $416000.0 in Q3 2024, and $651000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 418,000.00 |
| Dec 31, 2024 | 418,000.00 |
| Sep 30, 2024 | 416,000.00 |
| Sep 30, 2024 | 416,000.00 |
| Jun 30, 2024 | 651,000.00 |
| Jun 30, 2024 | 651,000.00 |
| Mar 31, 2024 | 584,000.00 |
| Mar 31, 2024 | 584,000.00 |
| Dec 31, 2023 | 584,000.00 |
| Dec 31, 2023 | 584,000.00 |
| Sep 30, 2023 | 583,000.00 |
| Sep 30, 2023 | 583,000.00 |
| Jun 30, 2023 | 584,000.00 |
| Jun 30, 2023 | 584,000.00 |
| Mar 31, 2023 | 584,000.00 |
| Mar 31, 2023 | 584,000.00 |
| Dec 31, 2022 | 584,000.00 |
| Dec 31, 2022 | 584,000.00 |
| Sep 30, 2022 | 583,000.00 |
| Sep 30, 2022 | 583,000.00 |